Terms: = Cervical cancer AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306
13 results:
1. Recruitment strategies to promote uptake of cervical cancer screening in the West Region of Cameroon.
Pham MA; Benkortbi K; Kenfack B; Tincho Foguem E; Sormani J; Wisniak A; Lemoupa Makajio S; Manga E; Vassilakos P; Petignat P
BMC Public Health; 2022 Mar; 22(1):548. PubMed ID: 35305588
[TBL] [Abstract] [Full Text] [Related]
2. Primary Synovial Sarcoma of the Uterine Cervix: First Case Report.
Vaziri Fard E; Zhang S; El Achi HS; Covinsky M
Int J Gynecol Pathol; 2021 Mar; 40(2):196-203. PubMed ID: 33075021
[TBL] [Abstract] [Full Text] [Related]
3. Long-term evaluation of renal function and neurogenic bladder following radical hysterectomy in patients with uterine cervical cancer.
Komatsu H; Oishi T; Osaku D; Kudoh A; Shimogai R; Chikumi J; Sato S; Harada T
J Obstet Gynaecol Res; 2020 Oct; 46(10):2108-2114. PubMed ID: 32686280
[TBL] [Abstract] [Full Text] [Related]
4. cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.
Marie-Egyptienne DT; Chaudary N; Kalliomäki T; Hedley DW; Hill RP
Oncotarget; 2017 Jan; 8(1):1392-1404. PubMed ID: 27901496
[TBL] [Abstract] [Full Text] [Related]
5. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
[TBL] [Abstract] [Full Text] [Related]
6. Clonality analysis of synchronous lesions of cervical carcinoma based on X chromosome inactivation polymorphism, human papillomavirus type 16 genome mutations, and loss of heterozygosity.
Hu X; Pang T; Asplund A; Pontén J; Nistér M
J Exp Med; 2002 Apr; 195(7):845-54. PubMed ID: 11927629
[TBL] [Abstract] [Full Text] [Related]
7. Sequence variations of the late upstream region of HPV16 in cervical intraepithelial neoplasm and invasive carcinoma.
Pang T; Hu X; Ponten J
Int J Gynecol Cancer; 2002; 12(1):99-104. PubMed ID: 11860543
[TBL] [Abstract] [Full Text] [Related]
8. Immune reactive proteins in patients irradiated for cervical cancer. One year follow up.
Juranić Z; Vucković-Dekić L; Durbaba M
Neoplasma; 1994; 41(4):225-8. PubMed ID: 7935997
[TBL] [Abstract] [Full Text] [Related]
9. cervical carcinoma: a comparison of four potential biochemical tumor markers.
Dodd JK; Henry RJ; Tyler JP; Houghton CR
Gynecol Oncol; 1989 Feb; 32(2):248-52. PubMed ID: 2910788
[TBL] [Abstract] [Full Text] [Related]
10. Immune reactive proteins as prognostic and clinical markers in malignant cervical neoplasia.
Radhakrishna Pillai M; Balaram P; Hareendran NK; Bindu S; Abraham T; Padmanabhan TK; Nair MK
J Cancer Res Clin Oncol; 1989; 115(6):583-91. PubMed ID: 2606934
[TBL] [Abstract] [Full Text] [Related]
11. Quantification of polyethylene glycol precipitable circulating immune complex from carcinoma of cervix patients.
Das S
Arch Geschwulstforsch; 1987; 57(4):283-6. PubMed ID: 3675140
[TBL] [Abstract] [Full Text] [Related]
12. The fluctuation of circulating immune complexes level in patients with malignancy.
Vodvárka P; Vodvárka T; Foukalová J
Neoplasma; 1984; 31(4):485-9. PubMed ID: 6472521
[TBL] [Abstract] [Full Text] [Related]
13. Circulating IgG-specific immune complexes as a potential tumor marker in gynecological malignancies.
Dodd JK; Hicks LJ; Tyler JP; Crandon AJ; Hudson CN
Gynecol Oncol; 1983 Oct; 16(2):232-9. PubMed ID: 6629124
[TBL] [Abstract] [Full Text] [Related]
